vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and Western New England Bancorp, Inc. (WNEB). Click either name above to swap in a different company.

Western New England Bancorp, Inc. is the larger business by last-quarter revenue ($22.0M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). Western New England Bancorp, Inc. runs the higher net margin — 23.7% vs -1398.3%, a 1422.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 18.8%). Western New England Bancorp, Inc. produced more free cash flow last quarter ($17.1M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 10.5%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

The Bank of New England Corporation refers to a current online real estate bank based in New Hampshire and former regional banking institution based in Boston, Massachusetts, which was seized by the Federal Deposit Insurance Corporation (FDIC) in 1991 as a result of heavy losses in its loan portfolio and was placed into Chapter 7 liquidation. At the time, it was the 33rd largest bank in the United States, and its federal seizure bailout was the second-largest on record. At its peak, it had be...

RNA vs WNEB — Head-to-Head

Bigger by revenue
WNEB
WNEB
1.8× larger
WNEB
$22.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+415.3% gap
RNA
434.0%
18.8%
WNEB
Higher net margin
WNEB
WNEB
1422.0% more per $
WNEB
23.7%
-1398.3%
RNA
More free cash flow
WNEB
WNEB
$174.0M more FCF
WNEB
$17.1M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
10.5%
WNEB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
WNEB
WNEB
Revenue
$12.5M
$22.0M
Net Profit
$-174.4M
$5.2M
Gross Margin
Operating Margin
-1513.5%
30.1%
Net Margin
-1398.3%
23.7%
Revenue YoY
434.0%
18.8%
Net Profit YoY
-117.0%
58.4%
EPS (diluted)
$-1.27
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
WNEB
WNEB
Q4 25
$22.0M
Q3 25
$12.5M
$21.3M
Q2 25
$3.8M
$21.1M
Q1 25
$1.6M
$18.3M
Q4 24
$3.0M
$18.5M
Q3 24
$2.3M
$17.9M
Q2 24
$2.0M
$18.3M
Q1 24
$3.5M
$18.0M
Net Profit
RNA
RNA
WNEB
WNEB
Q4 25
$5.2M
Q3 25
$-174.4M
$3.2M
Q2 25
$-157.3M
$4.6M
Q1 25
$-115.8M
$2.3M
Q4 24
$-102.3M
$3.3M
Q3 24
$-80.4M
$1.9M
Q2 24
$-70.8M
$3.5M
Q1 24
$-68.9M
$3.0M
Operating Margin
RNA
RNA
WNEB
WNEB
Q4 25
30.1%
Q3 25
-1513.5%
19.7%
Q2 25
-4448.7%
28.6%
Q1 25
-8360.9%
16.2%
Q4 24
-4069.6%
23.5%
Q3 24
-4200.9%
14.1%
Q2 24
-4040.4%
23.4%
Q1 24
-2178.6%
21.0%
Net Margin
RNA
RNA
WNEB
WNEB
Q4 25
23.7%
Q3 25
-1398.3%
14.9%
Q2 25
-4089.3%
21.8%
Q1 25
-7360.0%
12.6%
Q4 24
-3439.5%
17.7%
Q3 24
-3441.7%
10.7%
Q2 24
-3461.8%
19.2%
Q1 24
-1943.4%
16.4%
EPS (diluted)
RNA
RNA
WNEB
WNEB
Q4 25
$0.25
Q3 25
$-1.27
$0.16
Q2 25
$-1.21
$0.23
Q1 25
$-0.90
$0.11
Q4 24
$-0.80
$0.16
Q3 24
$-0.65
$0.09
Q2 24
$-0.65
$0.17
Q1 24
$-0.79
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
WNEB
WNEB
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$247.6M
Total Assets
$2.1B
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
WNEB
WNEB
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
RNA
RNA
WNEB
WNEB
Q4 25
$247.6M
Q3 25
$1.9B
$243.6M
Q2 25
$1.2B
$239.4M
Q1 25
$1.3B
$237.7M
Q4 24
$1.4B
$235.9M
Q3 24
$1.5B
$240.7M
Q2 24
$1.2B
$236.5M
Q1 24
$830.9M
$235.8M
Total Assets
RNA
RNA
WNEB
WNEB
Q4 25
$2.7B
Q3 25
$2.1B
$2.7B
Q2 25
$1.4B
$2.7B
Q1 25
$1.5B
$2.7B
Q4 24
$1.6B
$2.7B
Q3 24
$1.6B
$2.6B
Q2 24
$1.3B
$2.6B
Q1 24
$951.5M
$2.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
WNEB
WNEB
Operating Cash FlowLast quarter
$-156.2M
$18.2M
Free Cash FlowOCF − Capex
$-156.9M
$17.1M
FCF MarginFCF / Revenue
-1257.6%
77.9%
Capex IntensityCapex / Revenue
5.7%
4.9%
Cash ConversionOCF / Net Profit
3.50×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
WNEB
WNEB
Q4 25
$18.2M
Q3 25
$-156.2M
$5.6M
Q2 25
$-199.7M
$6.8M
Q1 25
$-124.8M
$-1.2M
Q4 24
$-99.9M
$12.2M
Q3 24
$-65.6M
$3.0M
Q2 24
$-65.0M
$2.0M
Q1 24
$-70.4M
$1.2M
Free Cash Flow
RNA
RNA
WNEB
WNEB
Q4 25
$17.1M
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
$11.0M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
RNA
RNA
WNEB
WNEB
Q4 25
77.9%
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
59.2%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
RNA
RNA
WNEB
WNEB
Q4 25
4.9%
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
6.5%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
RNA
RNA
WNEB
WNEB
Q4 25
3.50×
Q3 25
1.76×
Q2 25
1.49×
Q1 25
-0.54×
Q4 24
3.70×
Q3 24
1.57×
Q2 24
0.56×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons